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Introduction: Pemetrexed has established efficacy, and is the back-
bone for chemotherapy in patients with malignant pleural mesothe-
lioma (MPM). An International Expanded Access Program provided
3000 mesothelioma patients with access to single-agent pem-
etrexed or pemetrexed plus platinum analogs (cisplatin or carbopla-
tin) in 13 countries. In this article, we report the safety and efficacy
data of MPM patients who were treated with single-agent pem-
etrexed (n  812).
Methods: Patients with histologically confirmed MPM, not amena-
ble to curative surgery, received pemetrexed (500 mg/m2) once (day
1) every 21 days with standard premedication and vitamin supple-
mentation. Investigator-determined response and survival data were
recorded at the end of study participation. Myelosuppression data
were also collected.
Results: All 812 MPM patients (319 chemonaı¨ve; 493 pretreated)
received single-agent pemetrexed (1 dose) and were evaluated for
safety. A total of 643 patients (247 chemonaı¨ve, 396 pretreated)
were evaluated for efficacy. Of the chemonaı¨ve patients evaluated
for efficacy (n  247), the overall response rate was 10.5%, median
time to progressive disease (TTPD) was 6.0 months, and median
survival was 14.1 month. Of the pretreated patients evaluated for
efficacy (n  396), the overall response rate was 12.1%, median
TTPD was 4.9 months, and the median survival was not estimable
due to high censoring. Common terminology criteria grade 3/4
hematologic toxicity was mild in both groups, with neutropenia
(18%) as the main toxicity.
Conclusions: In the present expanded access program, single-
agent pemetrexed demonstrated promising activity in MPM in
both chemonaı¨ve and pretreated patients, with TTPD of 6.0 and
4.9 months, respectively, 1-year survival 54.7%, and mild
hematologic toxicity.
Key Words: Chemonaı¨ve, Expanded access program, Malignant
pleural mesothelioma, Pemetrexed, Pretreated patients.
(J Thorac Oncol. 2008;3: 764–771)
Malignant pleural mesothelioma (MPM) is a rapidlyprogressive malignancy, with a median survival shorter
than 1 year,1 that is typically associated with prior exposure
to asbestos.2 Although a number of chemotherapy regimens
have been evaluated in the past 2 decades, no single-agent
treatments have been associated with prolonged survival.3–6
Anthracyclines, cisplatin, carboplatin, mitomycin, and
ifosfamide were evaluated extensively in phase II trials, in
which response rates varying from 14 to 24% and survival
times shorter than 1 year were reported.3 Ellis et al. conducted
a systematic review of chemotherapy in patients with ad-
vanced MPM5 and concluded that the pooled overall response
rate for single-agent treatment and nonplatinum combination
treatment was less than 10% and less than 12%, respectively.
Platinum-based combinations were more active, with an
overall response rate of approximately 25%.
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Antifolates such as raltitrexed, trimetrexate, edatrexate,
and methotrexate have been evaluated in single-agent phase
II studies of patients with MPM. Although these antifolates
demonstrated activity against MPM, evidence supporting
their use in clinical practice remains uncertain.7–10 Combina-
tion chemotherapy of raltitrexed plus cisplatin was superior to
single-agent cisplatin in a randomized trial.11
Pemetrexed is a multitargeted antifolate agent that
inhibits multiple enzymes in the folate pathway and has
broad antitumor activity in multiple tumor types, including
MPM.12,13 Single-agent pemetrexed received regulatory ap-
proval as second-line treatment in advanced nonsmall cell
lung cancer,14 and a phase II trial of single-agent pemetrexed
as front-line therapy for MPM showed an overall response
rate of 14.1% and a median survival of 10.7 months.13 Higher
response rates with improved survival were seen in MPM
patients when pemetrexed was combined with platinum an-
alogs.15,16 A randomized phase III study of pemetrexed plus
cisplatin versus cisplatin in chemonaı¨ve patients with MPM
showed a response rate of 41.3 versus 16.7% and a median
survival of 12.1 versus 9.3 months, in favor of the combina-
tion arm.17 On the basis of the high response rate and the
improvement in overall survival, pemetrexed in combination
with cisplatin was approved by the United States Food and
Drug Administration in February 2004 for the treatment of
patients with MPM who had unresectable disease or who
were not candidates for curative surgery.18 Similar approvals
were also granted by European regulatory agencies.
Although the randomized study demonstrated prom-
ising results for pemetrexed plus cisplatin,17 many patients
may not be eligible for platinum-containing regimens be-
cause of comorbidities, age, and performance status. For this
group of patients, single-agent pemetrexed may be a prefer-
rable option.
To further extend the clinical benefit of pemetrexed in
patients with mesothelioma, an international Expanded Ac-
cess Program (EAP) provided patients in 13 European coun-
tries with access to pemetrexed (either as pemetrexed-plati-
num combination therapy or as single-agent therapy) before
its commercial availability. The primary objective was to
provide patients access to pemetrexed, and the secondary
objectives included basic safety data collection, determina-
tion of overall best tumor response, and determination of time
to progressive disease (TTPD). This report presents results
for MPM patients (both chemonaı¨ve and pretreated) who
received treatment with single-agent pemetrexed in the EAP.
The subset of patients who received pemetrexed in combination
with either cisplatin or carboplatin appears to differ in terms of
comorbidities, age, and performance status and was therefore
not included in the present analysis. Key results for the other
patient subgroups were presented previously.19,20
PATIENTS AND METHODS
Patients
Patients with a histologically proven diagnosis of me-
sothelioma who were at least 18-year-old and were not
candidates for curative surgery were enrolled in this EAP.
Patients were clinically staged using the International Me-
sothelioma Interest Group Tumor Nodes Metastasis staging
criteria.21 Measurable lesions were not required for enroll-
ment. Patients could have been chemonaı¨ve or may have
received one or more lines of prior chemotherapy for malig-
nant mesothelioma. Patients who had prior treatment with
pemetrexed were eligible if they had a tumor response or
received a clinical benefit from prior pemetrexed treatment.
Patients were required to have a performance status 70 on
the Karnofsky scale (KPS) (after any palliative measure,
including pleural drainage, had occurred). Patients were re-
quired to have adequate bone marrow reserve (absolute neu-
trophil count [ANC] 1.5  109/L, platelets 100  109/L,
and hemoglobin 9 g/dL), adequate hepatic function (biliru-
bin 1.5 times the upper limit of normal [ULN], alkaline
phosphatase, aspartate transaminase, and alanine transaminase
3.0 ULN or alkaline phosphatase, aspartate transaminase,
and alanine transaminase 5 ULN if liver had tumor
involvement), and adequate renal function (calculated creat-
inine clearance 45 mL/min) based on the standard Cockroft
and Gault formula.22 Patients with adequately treated and
stable brain metastases not requiring corticosteroid therapy
were allowed. Prior pleurodesis was allowed. Pregnant
women were not eligible, and all men and women of repro-
ductive potential were required to use an approved method of
birth control. Patients with active infection were excluded.
Patients with serious concomitant disorders incompatible
with the study were excluded at the investigator’s decision.
Institutional ethical review boards approved the protocol and
the study was conducted according to Good Clinical Practice
guidelines and the Declaration of Helsinki. All patients pro-
vided written informed consent before treatment.
Treatment Plan
In this International EAP, patients were assigned to one
of the following three options: pemetrexed plus cisplatin,
pemetrexed plus carboplatin, or single-agent pemetrexed. The
primary treatment option for patients in this EAP was pem-
etrexed plus cisplatin, but patients who could not tolerate the
cisplatin-based regimen were offered one of the other two
treatment options. Treatment allocation was done by individ-
ual investigators who considered the clinical status of each
patient. This report presents the results for patients with
MPM who received single-agent pemetrexed.
Pemetrexed 500 mg/m2 was administered intravenously
over 10 minutes on day 1 of a 21-day cycle. Folic acid
supplementation, 350 g to 600 g or equivalent, was given
orally daily beginning approximately 1 to 2 weeks before the
first dose of pemetrexed and continuing daily until at least 3
weeks after the last pemetrexed dose. A vitamin B12 injec-
tion, 1000 g, was administered intramuscularly approxi-
mately 1 to 2 weeks before the first dose of pemetrexed and
was repeated approximately every 9 weeks until the patient
was discontinued from the study therapy. In addition, dexa-
methasone 4 mg (or an equivalent corticosteroid) was given
orally twice per day on the day before, the day of, and the day
after each dose of pemetrexed to reduce the risk of severe
skin rash. Study therapy was allowed to continue until there
was evidence of progressive disease or until the patient
experienced unacceptable toxicity, the investigator decided to
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discontinue the patient, the patient requested discontinuation,
or if Lilly decided to stop the EAP when pemetrexed became
commercially available.
Dose Adjustments
Dose adjustments at the start of a subsequent cycle of
therapy were based on platelet and neutrophil nadir (lowest
value) counts from the preceding cycle of therapy (ANC had
to be 1.5  109/L and platelets 100  109/L before the
start of any cycle). Dose delays up to 42 days were permitted
for recovery from study-drug toxicity. Upon recovery, the
treatment was resumed from the preceding cycle of therapy at
100% of the previous dose for an ANC 0.5  109/L and
platelets 50  109/L, at 75% of the previous dose for an
ANC 0.5  109/L and platelets 50  109/L, or at 50% of
the previous dose for platelets 50  109/L. Any patient
requiring 3 dose reductions was discontinued from the study.
In the event of diarrhea requiring hospitalization (or at least
grade 3), treatment was delayed until diarrhea had resolved
before proceeding. Treatment was then resumed at 75% of
the previous dose level. For other nonhematologic events
greater than or equal to grade 3 (with the exception of grade
3 transaminase elevation), treatment was delayed until reso-
lution to less than or equal to the patient’s baseline grade
before proceeding. Treatment was then resumed at 75% of
the previous dose level if deemed appropriate by the treating
physician.
Efficacy Assessments
Patients’ tumor response was assessed preferably using
Response Evaluation in Solid Tumors (RECIST) criteria23;
however, Southwest Oncology Group criteria or World
Health Organization criteria were also acceptable for re-
sponse evaluation. The best overall response rate was deter-
mined when the patient completed or was discontinued from
the study. The overall tumor response rate was defined as the
number of patients with documented partial response or
complete response divided by the number of patients quali-
fied for tumor response analysis (evaluable patients). TTPD
was estimated in months from the date of the first dose to the
date of the first documentation of progressive disease. Sur-
vival time was estimated in months from the date of the first
dose to the date of death. Survival status was recorded when
the patient completed therapy and at one follow-up visit 30
days after study completion.
Safety Assessments
Safety was assessed by physical examination and clin-
ical laboratory tests. Patients were rated for adverse events
before each cycle using the Common Terminology Criteria
for Adverse Events (CTCAE) scale, version 2. Serious ad-
verse events (SAEs) were required to be reported immedi-
ately by the investigators, and were monitored by the Eli Lilly
clinical research physician.
Statistical Methods
Summaries of statistics were provided. Missing data
were not considered in the efficacy or safety analysis. Only
the available data in each cycle were summarized. The
investigator-assessed overall best tumor response was sum-
marized with proportion and 95% confidence intervals (CIs).
TTPD and survival time were calculated using Kaplan-Meier
estimates. Patients for whom no follow-up observation was
available were censored. The log-rank test was conducted to
compare the chemonaı¨ve and the pretreated patient groups.
All subjects who received at least one dose of the study
drug were classified as the safety population. All patients who
were in the safety population and who had at least one tumor
response observation after baseline were classified as the
evaluable efficacy population.
RESULTS
Patient Characteristics and Disposition
A total of 3142 patients with MPMwere enrolled at 235
study centers in 13 countries; 2074 patients were chemonaı¨ve
and 1011 were pretreated (Figure 1). This manuscript de-
scribes the findings in a total of 812 patients with MPM who
received treatment with single-agent pemetrexed. Results for
other patient subgroups have been described previously.19,20
Detailed results for chemonaı¨ve patients who received pem-
etrexed and platinum combinations therapy will also be
described in a separate publication.
All 812 patients (319 chemonaı¨ve and 493 pretreated)
received at least one dose of single-agent pemetrexed and
constituted the safety population. Tumor response data were
available for 247 chemonaı¨ve patients and for 396 pretreated
patients.
Table 1 presents the baseline demographics and patient
characteristics. In both groups, the majority of patients were
male (75.9%) and Caucasian (99.4%). The median age of
patients in the chemonaı¨ve and pretreated group was 69 years
and 63 years, respectively. The majority of patients had a
KPS of 80 or higher (71.6% in the chemonaı¨ve group and
74.5% in the pretreated group). Four patients (1.4%) in the
chemonaı¨ve group had a KPS 70 and 3 patients (0.6%) in
the pretreated group had a KPS 70; these 7 patients were in
violation of the eligibility criteria requirements.
The main reasons for treatment discontinuation in both
of the study groups were objective tumor progression (25.4%
in chemonaı¨ve patients, 29.6% in pretreated patients), clinical
disease progression (16.6% in chemonaı¨ve patients, 13.2% in
pretreated patients), and patient-physician decision (13.5% in
chemonaı¨ve patients, 14.4% in pretreated patients). Sixty
three patients (24 chemonaı¨ve [7.5%] and 39 pretreated
[7.9%]) discontinued because of death from study disease.
Treatment
A median of 4 cycles (range, 1–18 cycles) was admin-
istered to the patients in the chemonaı¨ve group; similarly, a
median of 4 cycles (range, 1–23 cycles) was administered to
the patients in the pretreated group. In the chemonaı¨ve group,
126 patients (39.5%) received 6 cycles and 15 patients (4.7%)
received 12 treatment cycles. Similarly, in the pretreated
group, 186 patients (37.7%) received 6 cycles and 16 patients
(3.2%) received 12 cycles. The relative dose intensity of
pemetrexed (i.e., the percentage of dose delivered compared
with the planned dose) was 98.3% in the chemonaı¨ve group
and 97.9% in the pretreated group.
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Efficacy
Of the chemonaı¨ve patients assessable for response
(n  247), 1 (0.4%) had a complete response and 25 (10.1%)
patients had a partial response, resulting in an overall re-
sponse rate of 10.5% (Table 2). An additional 120 patients
(48.6%) had stable disease as their best tumor response and
86 (34.8%) had progressive disease. Of the pretreated patients
assessable for response (n  396), none had complete re-
sponse and 48 (12.1%) patients had a partial response, result-
ing in an overall response rate of 12.1%. An additional 182
patients (46.0%) had stable disease as their best tumor re-
sponse and 147 (37.1%) had progressive disease (Table 2).
TABLE 1. Baseline Demographics and Patient
Characteristics
Characteristic
Chemonaïve
Patients
(n  319)
Pretreated
Patients
(n  493)
Median age, yrs (range) 69.0 (39.0–87.0) 63.0 (31.0–85.0)
Gender, n (%)
Male 249 (78.1) 374 (75.9)
Female 70 (21.9) 119 (24.1)
Ethnic origin, n (%)
Caucasian 317 (99.4) 491 (99.6)
African descent 2 (0.6) 0
East/southeast 0 1 (0.2)
Other 0 1 (0.2)
Histological diagnosis, n (%)
Epithelial 195 (61.1) 351 (71.2)
Sarcomatoid 23 (7.2) 16 (3.2)
Mixed cells 19 (6.0) 28 (5.7)
Others 82 (25.7) 98 (19.9)
KPSa, n (%)
100 42 (14.2) 84 (17.9)
90 57 (19.3) 119 (25.3)
80 113 (38.2) 147 (31.3)
70 80 (27.0) 117 (24.9)
70 4 (1.4) 3 (0.6)
a KPS data available for 296 chemonaïve patients and 470 pretreated patients.
n, number of patients; KPS, Karnofsky performance status.
TABLE 2. Best Overall Response Rate (Evaluable Patients
Only)
Response
Chemonaïve
Patients
(n  247)
Pretreated
Patients
(n  396)
Complete response, n (%) 1 (0.4) 0 (0.0)
Partial response, n (%) 25 (10.1) 48 (12.1)
Stable disease, n (%) 120 (48.6) 182 (46.0)
Progressive disease, n (%) 86 (34.8) 147 (37.1)
Unknown, n (%) 15 (6.1) 19 (4.8)
Overall response rate, % 10.5 12.1
(95% CI) (7.0–15.0) (9.1–15.7)
Disease control rate (responder 
stable disease), %
59.1 58.1
(95% CI) (52.7, 65.3) (53.0, 63.0)
n, number of patients; CI, confidence interval.
FIGURE 1. MPM patients who en-
rolled in the pemetrexed International
Expanded Access Program. Abbrevia-
tions: EAP, expanded access program;
N, sample size; n, number of sub-
jects; Pem, pemetrexed. Note: the
highlighted boxes are the patient
population described in this manu-
script.
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The disease control rate (complete response  partial re-
sponse  stable disease) for chemonaı¨ve and pretreated
patients was 59.1 and 58.1%, respectively.
Results for median TTPD, median survival, and 1-year
survival rates for the efficacy evaluable population are pre-
sented in Table 3. The median TTPD was 6.0 months in the
chemonaı¨ve group and 4.9 months in the pretreated group
(Figure 2). Median survival could not be estimated in the
pretreated group because of a high censoring rate (78.9%);
however, the 1-year survival rate was 54.7%.
Per an intent-to-treat analysis, median survival was also
estimated for all treated patients with MPM who received
single-agent pemetrexed (n  812). For all treated patients in
the chemonaı¨ve group (n  319), the median survival was
14.1 month (95% CI, 10.4 months–16.4 months) and the
1-year survival rate was 53.9% (95% CI, 41.7–66.2%). For
all pretreated patients with MPM who received single-agent
pemetrexed (n  493), the median survival was 9.5 months
(95% CI, 8.6 months–not estimable) and the 1-year survival
rate was 47.2% (95% CI, 36.3–58.1%).
Safety
Only myelotoxicity data were collected. The most often
reported CTCAE grade 3 and 4 toxicities observed in each
group are summarized in Table 4. Of 319 chemonaı¨ve pa-
tients and 493 pretreated patients, respectively, CTCAE grade
3/4 toxicities observed in 10% of the patients were neutro-
penia (17.3 and 15.6%) and leukopenia (14.7 and 13.9%).
SAEs, which were monitored by the Lilly Safety Sys-
tem, reported in 1% of patients in the chemonaı¨ve group
were: nausea (3.4%), vomiting (3.1%), thrombocytopenia
(3.1%), anemia (1.6%), neutropenia (1.3%), and diarrhea
(1.3%). SAEs reported in 1% of patients in the pretreated
group were: anemia (2.2%), pancytopenia (1.6%), nausea
(1.6%), vomiting (1.6%), neutropenia (1.0%), and sepsis
(1.0%). During the study, 11 deaths were considered possibly
related to study-drug toxicity by the investigators. Four of
these deaths occurred in the chemonaı¨ve group (1 each
caused by neutropenic sepsis, pancytopenia, acute respiratory
TABLE 3. Time to Progressive Disease and Survival Results
in Efficacy Evaluable Population
Event
Chemonaïve Patients
(n  247)
Pretreated Patients
(n  396)
Median TTPD, mo 6.0 4.9
(95% CI) (4.6, 7.2) (4.2, 5.8)
Median survival, mo 14.1 NE
(95% CI) (10.4, 16.4) (8.8, NE)
One-year survival rate, % 58.6 54.7
(95% CI) (43.4, 73.8) (42.6, 66.8)
Censor rate, % 79.3 78.9
n, number of patients; TTPD, time to progressive disease; CI, confidence interval;
NE, not estimable due to the large percent of censored records.
FIGURE 2. Kaplan-Meier analysis of time to progressive disease (months) in patients with MPM who received single-agent
pemetrexed. Evaluable population consisted of chemonaı¨ve patients (n  247) and previously treated patients (n  396).
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failure, and unknown cause), and 7 deaths occurred in the
pretreated group (2 caused by neutropenic sepsis, 2 caused by
septic shock, and 1 each caused by ileus, sepsis, and pancy-
topenia).
DISCUSSION
The phase III randomized study reported by Vogelzang et
al. demonstrated that the combination of pemetrexed and cispla-
tin was more effective than cisplatin monotherapy in MPM.
Although the combination was associated with higher response
rates and improved survival and quality of life,17 platinum-
containing regimens may be inappropriate for elderly patients
with comorbidities and a poor performance status.
In the current European EAP, chemonaı¨ve and pre-
treated patients with MPM who received single-agent pem-
etrexed demonstrated similar response rates of 10.5 and
12.1%, and a 1-year survival rate of 58.6 and 54.7%, respec-
tively. In addition, the median survival time of 14.1 month in
the chemonaı¨ve group was notable.
Comparing response rates observed in the present EAP
with those reported for other clinical studies presents a
challenge since the protocol did not use the now widely
accepted “modified RECIST” guidelines. The EAP protocol
was less restrictive and allowed the use of RECIST, South-
west Oncology Group, or World Health Organization criteria
to assess response. Still, the present EAP demonstrated higher
response rates and longer survival as compared with a similar
EAP conducted in the United States (Table 5), which allowed
similar flexibility in the criteria used to evaluate response in
MPM.24,25 In the United States EAP, the response rate for
chemonaı¨ve and pretreated patients was 6.7%24 and 5.5%,25
and respective median survival times were 4.8 months24 and
4.1 month.25 The observed differences in efficacy between
the two programs could be related to differences in popula-
tion characteristics such as age, performance status, and
regional or ethnic characteristics. A multicenter phase II
study in 43 vitamin-supplemented chemonaı¨ve patients re-
ceiving single-agent pemetrexed showed a response rate that
was similar to the present study (Table 5).13 Studies evaluat-
ing other antifolates (raltitrexed, trimetrexate, edatrexate, and
methotrexate) in chemonaı¨ve patients reported higher overall
response rates, from 12 to 37%, than this European EAP.
Overall survival times of 7 to 11 months were, however,
shorter than in the present EAP (Table 5).7–10 In a randomized
phase III study of single-agent pemetrexed with best support-
ive care (BSC) versus BSC for second-line chemotherapy in
patients with MPM,26 the overall response rate (19.2 versus
1.7%) and median TTPD (3.8 months versus 1.5 months)
were in favor of the pemetrexed with BSC arm. The median
survival (8.6 versus 9.7 months), however, was not signifi-
cantly different on the two arms, probably because of the use
of poststudy chemotherapy in the BSC arm. Sorensen et al.
studied the feasibility of single-agent pemetrexed as second-
line therapy for patients with MPM who had previously
received a platinum-based regimen.27 For these 28 patients
who received pemetrexed as second-line chemotherapy, the
response rate, median survival, and 1-year survival rate was
21%, 9.8 months, and 36%, respectively. Another study
demonstrated the role of single-agent pemetrexed as mainte-
nance therapy in patients with MPM.28 Although only 27
TABLE 5. Studies of Single-agent Antifolates in Chemonaïve Patients with Malignant
Pleural Mesothelioma
Agent Authors
No.
of Pts
Overall
Response
Rate (%)
Median
Survival (mo)
One-year
Survival
Rate (%)
Pemetrexed
(current EU EAP)
Taylor et al. 812 10.5 14.1 53.9
Pemetrexed
(US EAP)
Obasaju et al.24 19 6.7 4.8 0
Pemetrexed Scagliotti et al.13 64 14.1 10.7 47.8
Raltitrexed Baas et al.7 24 20.8 7.0 NA
Edatrexate Kindler et al.9 20 25.0 9.6 50.0
Trimetrexate Vogelzang et al.8 NA
Low-dose cohort 17 12.0 5.0
High-dose cohort 35 12.0 8.9
Methotrexate Solheim et al.10 63 37.0 11.0 NA (2-yr  32)
No., number; Pts, patients; EAP, expanded access program; NA, not available or not reported.
TABLE 4. CTCAE Grade 3/4 Hematologic Toxicity in
Patients who Received Single-agent Pemetrexed (Safety
Population)
Toxicitya
Chemonaïve Patients
(n  319)b
Pretreated Patients
(n  493)c
Neutropenia, % 17.3 15.6
Leukopenia, % 14.7 13.9
Anemia, % 7.5 9.2
Thrombocytopenia, % 2.9 4.9
a Only myelosuppression data were collected.
b Of the 319 chemonaïve patients, 301 patients had at least one observation for
neutrophils, and 306 patients had at least one observation for the other 3 toxicity
parameters.
c Of the 493 pretreated patients, 461 patients had at least one observation for
neutrophils, and 469 patients had at least one observation for the other 3 toxicity
parameters.
CTCAE, Common Terminology Criteria for Adverse Events; n, number of patients.
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patients were enrolled in that study, the findings suggest that
patients who received single-agent pemetrexed as mainte-
nance therapy (range of 8–20 cycles) had approximately
3-fold longer time to progression and survival.
Hematologic toxicity observed in the EAP was mild,
and similar to that seen in a previously reported phase II study
of single-agent pemetrexed.13 Likewise, the incidence of
SAEs in this large group of patients was comparatively low,
especially given that these patients were not considered
suitable for pemetrexed plus platinum combination therapy.
A substantial number of patients in the present EAP, in both
the chemonaı¨ve and the pretreated groups, received 6 or more
cycles of chemotherapy, suggesting that single-agent pem-
etrexed was generally well tolerated. The tolerability of
pemetrexed allows prolonged administration of this agent,
which may translate to prolonged survival.
The efficacy and safety results of this EAP supplement
the current clinical information regarding the use of pem-
etrexed in MPM. Although the overall response rate was low
compared with previous reports, the median TTPD (6.0
months and 4.9 months) and 1-year survival rates (58.6 and
54.7%) were respectable in both chemonaı¨ve and pretreated
patients with MPM. Hematologic toxicity was mild. Impor-
tant limitations of this study restrict how broadly these results
can be generalized. One inherent weakness of a compassion-
ate-use program is that certain data are not rigorously col-
lected. An inordinately large percentage of patients had a
histologic diagnosis of “other,” for example, making it diffi-
cult to assess the baseline condition of these patients relative
to patient groups described in previous studies. In addition,
tumor response designations could have been applied incon-
sistently because the study protocol allowed for several dif-
ferent methodologies to evaluate response. Response rates for
pretreated patients should be interpreted with greater caution
since having a response to prior therapy could have affected
the likelihood of response in this EAP. Although prior treat-
ment with pemetrexed was allowed, the timing and logistics
of this program suggest that a relatively small proportion of
patients received this agent as prior therapy. Despite these
limitations, the results presented here appear to confirm, in a
community setting, the activity of single-agent pemetrexed
and suggest a possible role for this regimen in patients with
MPM who cannot tolerate platinum-based therapy.
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